Moderna initiates phase III study of RSV vaccine
The US-based biotech company now enters the last phase with its vaccine candidate against RSV.
by VICTOR EMIL KRISTENSEN, translated by daniel pedersen
US-based Moderna is entering the final sprint in the race to have the first vaccine against respiratory syncytial virus (RSV), as reported by Danish business daily Børsen in connection with a company press release, which declared that two successful phase II trials have opened the pathway to a phase III study.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Glaxosmithkline halts RSV trial after safety recommendation
For subscribers
Bavarian Nordic on FDA special status: A huge validation
For subscribers
Bavarian's biggest competitors have a landmark 2022 ahead
For subscribers
